Join the conversation:
Home
Contact Us
About Halozyme
About Halozyme
Executive Management
Board of Directors
Corporate Governance
Location & Directions
Corporate Compliance
Newsroom
Newsroom
News Releases
Events & Webcasts
Glossary
Technology
Technology
ENHANZE™ Technology
Journals, Abstracts & Posters
Partnering
Products & Pipeline
Products
HYLENEX® recombinant
Pipeline
Analog Insulin - PH20
PEGPH20
HTI-501
Roche Products
Pfizer Products
Baxter-HyQ
ViroPharma - Cinryze
®
Intrexon-Alpha 1-Antitrypsin
Investors
Investors
Stock Information
News Releases
SEC Filings
Analyst Coverage
2013 Annual Meeting Materials
Events & Webcasts
Email Alerts
Investor FAQs
RSS Feeds
Careers
Careers
Corporate Culture
Career Opportunities
Investigators
Investors
Investors
Investors
Stock Information
News Releases
SEC Filings
Analyst Coverage
2013 Annual Meeting Materials
Events & Webcasts
Email Alerts
Investor FAQs
RSS Feeds
Investors
Stock Information
News Releases
SEC Filings
Analyst Coverage
2013 Annual Meeting Materials
Events & Webcasts
Email Alerts
Investor FAQs
RSS Feeds
Home
>
Investors
>
SEC Filings
>
SEC Fillings Details
03/12/2012
10-K
Annual Report
Website Design: Hane Chow Inc.
© 2011, 2012 Halozyme, Inc. All rights reserved.
Powered By Q4 Web Systems
3.8.1.5343